Senovia BiosciencesPartnering
Partner data room · SNV-102 · Obesity and cardiometabolic disease

The benefits of ketosis, alone and with incretins

SNV-102 is a once-daily oral drug in development for obesity and type 2 diabetes. It is designed to deliver the benefits of ketosis without the diet, alone or alongside GLP-1-based medicines.

In this briefing
  • Five-week diet-induced obesity data against a calorie-matched vehicle
  • Glucose tolerance
  • Semaglutide combination study, results November 2026
  • Market breadth and partnering structure

Access the briefing

For pharmaceutical, biotech and investment professionals. Use your work email.

I have an access code

Senovia will use these details only to follow up about this program. Nonconfidential summary. Composition, study reports and patent claim charts are shared under a confidentiality agreement.